(MEMPHIS, Tenn. – October 28, 2026) Trillions of bacteria live in the human gut without triggering an immune response. Scientists at St. Jude Children’s Research Hospital have now discovered a gene-regulatory pathway that helps maintain this delicate balance. Published today in Science Advances , they showed that a type of immune cell, regulatory T cells, co-opt a well-known general gene expression pathway called COMPASS to suppress inappropriate immune responses and prevent lethal inflammation and autoimmunity.
Within the body, immune cells distinguish between self and non-self, eliminating that which they consider non-self, such as viruses and bacteria. In the gut, this is complicated by the presence of the intestinal microbiota, a community of beneficial bacteria that live there. Regulatory T cells stop other immune cells from inappropriately reacting to these bacteria, though what genetic factors govern the process were poorly understood. To identify those factors, the St. Jude scientists used a CRISPR screen, uncovering that the gene Wdr82 , a key component of the gene activation pathway COMPASS, plays an essential role in enabling regulatory T cells to maintain intestinal immune tolerance.
“We found that under normal conditions, the COMPASS pathway enables regulatory T cells to prevent inflammation and autoimmunity in the intestine,” said corresponding author Yongqiang Feng , PhD, St. Jude Department of Immunology . “When this pathway is compromised, the immune system no longer recognizes these bacteria as harmless but rather treats them as inflammatory triggers.”
When the researchers deleted Wdr82 in T cells in mouse models, severe inflammation and autoimmunity developed in the intestine and, to a lesser extent, in the heart and lungs, eventually becoming lethal. Introducing functional regulatory T cells with intact Wdr82 to these models reversed the disease process and prevented death. Similarly, antibiotic treatment, which depleted most of the gut bacteria, prevented inflammation and stopped its catastrophic consequences.
“Our results suggest that regulatory T cells with defects in the COMPASS pathway cannot act as a protective barrier between gut bacteria and the inflammatory responses of other immune cells,” Feng said.
Shared pathway with a specialized role sets a new precedent
Although Wdr82 is expressed across T-cell types, its loss did not affect all subtypes equally. Regulatory T cells lost their protective function, while inflammatory effector T cells retained their activity. The findings reveal that a broadly used gene-regulatory pathway can have a specialized role in maintaining immune balance, challenging the prevailing assumption that such pathways function similarly across cell types.
“As a field, we’ve assumed that the general gene expression regulators like Wdr82 have universal functions in every type of T cell,” Feng said. “Our study introduces a new concept: General regulatory factors can have asymmetric effects across T-cell subtypes, performing specialized roles in particular immunological processes.”
This discovery sets a precedent that asymmetry may be hiding sources of unexplained autoimmunity, as scientists have often excluded broadly expressed genes from their analyses, assuming they function similarly in all cell types. Examining how general gene-regulatory pathways operate in specific immune cell populations may help researchers reveal previously overlooked mechanisms, leading to a better understanding of inflammatory bowel disease, food allergies and other as-yet uncurable autoimmune conditions.
“We are excited because genetic variations found in patients with autoimmune diseases may have been dismissed as potential causes because they appeared to be irrelevant to T cells as a whole,” Feng said. “Now, we can begin looking back at these variants to determine whether they selectively affect a particular T-cell subtype, understand how they cause disease and then open the path to creating novel treatments.”
Authors and funding
The study’s co-first authors are Wenjun Huang and Jun Li, of St. Jude. The study’s other authors are Minghong He, Beisi Xu, Wojciech Rosikiewicz, Xiaolei Hao, Menglin Jiang, Lu Bai, Siwei Zhang, Lei Li, Wenjie Qi, Vivek Choudhary, Min-Jhen Jheng, Ti-Cheng Chang, Laura Janke, Shondra Pruett-Miller, Kiran Kodali, Zuo-Fei Yuan, Anthony High, Hongjian Jin and Chunliang Li, all of St. Jude.
The study was supported by grants from the National Institutes of Health (R01AI190906, R01AI187465, R01AI153138, R21AI173909, R21AI163942 and P30CA021765) and the American Lebanese Syrian Associated Charities (ALSAC), the fundraising and awareness organization of St. Jude.
St. Jude Media Relations Contact
Michael Sheffield
Desk: (901) 595-0221
Cell: (901) 379-6072
michael.sheffield@stjude.org
media@stjude.org
St. Jude Children's Research Hospital
St. Jude Children’s Research Hospital is leading the way the world understands, treats, and cures childhood catastrophic diseases. From cancer to life-threatening blood disorders, neurological conditions, and infectious diseases, St. Jude is dedicated to advancing cures and means of prevention through groundbreaking research and compassionate care. Through global collaborations and innovative science, St. Jude is working to ensure that every child, everywhere, has the best chance at a healthy future. To learn more, visit stjude.org , read St. Jude Progress, a digital magazine , and follow St. Jude on social media at @stjuderesearch .
Science Advances
Experimental study
Cells
Wdr82-COMPASS coordinates Foxp3 and TCR signaling to sustain Treg control of microbiota-driven intestinal inflammation
28-Oct-2026